Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development
Authors:
Open Access
- 16 February 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 78 (4) , 953-964
Abstract
Background: The hollow-fibre system model of tuberculosis (HFS-TB) has been endorsed by regulators; however, application of HFS-TB requires a thorough understanding of intra- and inter-team variability, statistical power and quality controls.Methods: Three teams evaluated regimens matching those in the Rapid Evaluation of Moxifloxacin in Tuberculosis (REMoxTB) study, plus two high-dose rifampicin/pyrazinamide/moxifloxacin regimens, administered daily for up to 28 or 56 days against Mycobacterium tuberculosis (Mtb) under log-phase growth, intracellular growth or semidormant growth under acidic conditions. Target inoculum and pharmacokinetic parameters were pre-specified, and the accuracy and bias at achieving these calculated using percent coefficient of variation (%CV) at each sampling point and two-way analysis of variance (ANOVA).Results: A total of 10 530 individual drug concentrations, and 1026 individual cfu counts were measured. The accuracy in achieving intended inoculum was >98%, and >88% for pharmacokinetic exposures. The 95% CI for the bias crossed zero in all cases. ANOVA revealed that the team effect accounted for 20% difference in slope, with a power of >99%.Conclusions: HFS-TB is a highly tractable tool for choosing combination regimens with little variability between teams, and between replicates.Keywords
Funding Information
- Bill and Melinda Gates Foundation to Critical Path for TB Drug Regimens
This publication has 52 references indexed in Scilit:
- Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive TuberculosisNew England Journal of Medicine, 2014
- Serum Drug Concentrations Predictive of Pulmonary Tuberculosis OutcomesThe Journal of Infectious Diseases, 2013
- A Time-to-Event Pharmacodynamic Model Describing Treatment Response in Patients with Pulmonary Tuberculosis Using Days to Positivity in Automated Liquid Mycobacterial CultureAntimicrobial Agents and Chemotherapy, 2013
- Dose-Dependent Activity of Pyrazinamide in Animal Models of Intracellular and Extracellular Tuberculosis InfectionsAntimicrobial Agents and Chemotherapy, 2011
- Treatment of Active Pulmonary Tuberculosis in Adults: Current Standards and Recent AdvancesPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2009
- Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis DrugsAntimicrobial Agents and Chemotherapy, 2009
- Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice AnymoreClinical Infectious Diseases, 2007
- Selection of a Moxifloxacin Dose That Suppresses Drug Resistance inMycobacterium tuberculosis,by Use of an In Vitro Pharmacodynamic Infection Model and Mathematical ModelingThe Journal of Infectious Diseases, 2004
- Bactericidal and Sterilizing Activities of Antituberculosis Drugs during the First 14 DaysAmerican Journal of Respiratory and Critical Care Medicine, 2003
- The role of pyrazinamide in primary chemotherapy for pulmonary tuberculosisTubercle, 1984